Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.
Wei X, Hunt G, Abdool Karim SS, Naranbhai V, Sibeko S, Abdool Karim Q, Li JF, Kashuba AD, Werner L, Passmore JA, Morris L, Heneine W, Johnson JA. Wei X, et al. Among authors: sibeko s. J Infect Dis. 2014 Jun 15;209(12):1916-20. doi: 10.1093/infdis/jiu026. Epub 2014 Jan 16. J Infect Dis. 2014. PMID: 24436453 Free PMC article. Clinical Trial.
Preventing HIV infection in women: a global health imperative.
Abdool Karim Q, Sibeko S, Baxter C. Abdool Karim Q, et al. Among authors: sibeko s. Clin Infect Dis. 2010 May 15;50 Suppl 3(Suppl 3):S122-9. doi: 10.1086/651483. Clin Infect Dis. 2010. PMID: 20397940 Free PMC article. Review.
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group. Abdool Karim Q, et al. Among authors: sibeko s. Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Science. 2010. PMID: 20643915 Free PMC article. Clinical Trial.
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Mureithi MW, Poole D, Naranbhai V, Reddy S, Mkhwanazi NP, Sibeko S, Werner L, Abdool Karim Q, Abdool Karim S, Ndung'u T, Altfeld M; CAPRISA004 Trial Group. Mureithi MW, et al. Among authors: sibeko s. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):124-7. doi: 10.1097/QAI.0b013e31824f53a9. J Acquir Immune Defic Syndr. 2012. PMID: 22362152 Free PMC article.
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
Valley-Omar Z, Sibeko S, Anderson J, Goodier S, Werner L, Arney L, Naranbhai V, Treurnicht F, Abrahams MR, Bandawe G, Swanstrom R, Karim QA, Karim SS, Williamson C. Valley-Omar Z, et al. Among authors: sibeko s. J Infect Dis. 2012 Jul 1;206(1):35-40. doi: 10.1093/infdis/jis305. Epub 2012 May 2. J Infect Dis. 2012. PMID: 22551813 Free PMC article. Clinical Trial.
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
Garrett NJ, Werner L, Naicker N, Naranbhai V, Sibeko S, Samsunder N, Gray C, Williamson C, Morris L, Abdool-Karim Q, Abdool-Karim SS. Garrett NJ, et al. Among authors: sibeko s. J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):55-61. doi: 10.1097/QAI.0000000000000367. J Acquir Immune Defic Syndr. 2015. PMID: 25247433 Free PMC article. Clinical Trial.
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.
Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L; CAPRISA002 Study Team. Gray ES, et al. Among authors: sibeko s. J Virol. 2011 May;85(10):4828-40. doi: 10.1128/JVI.00198-11. Epub 2011 Mar 9. J Virol. 2011. PMID: 21389135 Free PMC article.
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS. Karim QA, et al. Among authors: sibeko s. Trials. 2011 Mar 7;12:67. doi: 10.1186/1745-6215-12-67. Trials. 2011. PMID: 21385354 Free PMC article. Clinical Trial.
Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive.
Ngcapu S, Masson L, Sibeko S, Werner L, McKinnon LR, Mlisana K, Shey M, Samsunder N, Karim SA, Karim QA, Passmore JA. Ngcapu S, et al. Among authors: sibeko s. J Reprod Immunol. 2015 Aug;110:14-21. doi: 10.1016/j.jri.2015.03.007. Epub 2015 Apr 22. J Reprod Immunol. 2015. PMID: 25956139 Free PMC article. Clinical Trial.
33 results